Neoadjuvant androgen deprivation therapy before radical prostatectomy: Who is unlikely to benefit?

British Journal of Urology

Volumn 79, Issue 2, 1997, Pages 221-225

  Rabbani, F ^a   Sullivan, L D ^a   Goldenberg, S L ^a   Stothers, L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Neoadjuvant; Pathology; Prostate specific antigen; Prostatic neoplasms; Radical prostatectomy

Indexed keywords

ADJUVANT; ANTIANDROGEN; CYPROTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TUMOR DIFFERENTIATION;

EID: 0031403674     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1997.26714.x     Document Type: Article

References (17)

1. Wahle S, Reznicek M, Fallon B, Platz C, Williams R. Incidence of surgical margin involvement in various forms of radical prostatectomy. Urology 1990; 36: 23-6
2. Cleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9
3. Goldenberg SL, Klotz LH, Jewett MAS et al. Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer. J Urol 1995; 153: 254A
4. Labrie F, Cusan L, Gomez J-L et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44 (Symposium Issue): 29-37
5. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr. Puras-Baez A, for the Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154: 424-8
6. Cher ML, Shinohara K, Breslin S, Vapnek J, Carroll PR. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostate cancer. Br J Urol 1995; 75: 771-7
7. Aprikian AG, Fair WR, Reuter VE, et al. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 1994; 74: 630-6
8. Spiessl B, Beahrs OH, Hermanek P et al., eds. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours, 3rd edn. Berlin: Springer-Verlag. 1992: 261-9
9. Gentry JF. Pelvic lymph node metastases in prostatic carcinoma: The value of touch imprint cytology. Am J Surg Pathol 1986; 10: 718-27
10. Theiss M, Wirth MP, Manseck A, Frohmuller HG. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995; 27: 13-7
11. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993; 150: 1845-50
12. Norušis MJ, SPSS Inc. SPSS for Windows: Advanced Statistics. Release 6.0. Chapter 1. Chicago: SPSS Inc, 1993: 1-30
13. Stamey TA, Villers AA. McNeal JE, Link PC, Freiha FS. Positive surgical margins at radical prostatectomy: Importance of the apical dissection. J Urol 1990; 143: 1166-72
14. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 1993; 150: 110-4
15. Narayan P, Gajendran V, Taylor SP et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205-12
16. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1 - 2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990; 144: 1180-4
17. Partin AW, Carter HB, Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-52